Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Imatinib in Androgen-Independent Prostate Cancer With Bone Metastases
NCT00084825Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2003
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Treatment efficacy at 12 weeks. Started May 2003; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00084825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084825.